China Pharma Announces the Entry of "At-The-Market" Equity Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 13 2024
0mins
Source: PRnewswire
Prospectus Filing: China Pharma Holdings, Inc. has filed a prospectus supplement with the SEC to potentially offer and sell up to $600,000 worth of common stock through an agreement with an investor, with sales dependent on market conditions.
Company Overview: China Pharma is a specialty pharmaceutical company focused on developing and marketing products for high-incidence diseases in China, supported by a nationwide distribution network and GMP-certified product lines.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
